EA201270661A1 - УСИЛИВАЮЩИЕ РАЗМНОЖЕНИЕ β-КЛЕТОК СОЕДИНЕНИЯ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ - Google Patents

УСИЛИВАЮЩИЕ РАЗМНОЖЕНИЕ β-КЛЕТОК СОЕДИНЕНИЯ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Info

Publication number
EA201270661A1
EA201270661A1 EA201270661A EA201270661A EA201270661A1 EA 201270661 A1 EA201270661 A1 EA 201270661A1 EA 201270661 A EA201270661 A EA 201270661A EA 201270661 A EA201270661 A EA 201270661A EA 201270661 A1 EA201270661 A1 EA 201270661A1
Authority
EA
Eurasian Patent Office
Prior art keywords
reinforcing
replacement
methods
application
cell connections
Prior art date
Application number
EA201270661A
Other languages
English (en)
Inventor
Джастин П. Аннес
Дуглас А. Мелтон
Ли Л. Рубин
Гордон Веир
Original Assignee
Президент Энд Феллоуз Оф Гарвард Колледж
Зе Бригхам Энд Вуменз Хоспитал, Инк.
Джослин Диабетес Сентер, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Президент Энд Феллоуз Оф Гарвард Колледж, Зе Бригхам Энд Вуменз Хоспитал, Инк., Джослин Диабетес Сентер, Инк. filed Critical Президент Энд Феллоуз Оф Гарвард Колледж
Publication of EA201270661A1 publication Critical patent/EA201270661A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/507—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/40—Nucleotides, nucleosides or bases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)

Abstract

Настоящее изобретение относится к способу стимуляции или усиления размножения или роста β-клеток путем контакта β-клетки с ингибитором аденозинкиназы (ADK), ингибитором S-аденозилгомоцистеингидролазы (SAHH) или активатором АМР-активируемой протеинкиназы (АМРК).
EA201270661A 2009-12-18 2010-12-17 УСИЛИВАЮЩИЕ РАЗМНОЖЕНИЕ β-КЛЕТОК СОЕДИНЕНИЯ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ EA201270661A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28800109P 2009-12-18 2009-12-18
PCT/US2010/061075 WO2011075665A2 (en) 2009-12-18 2010-12-17 Beta-cell replication promoting compounds and methods of their use

Publications (1)

Publication Number Publication Date
EA201270661A1 true EA201270661A1 (ru) 2013-06-28

Family

ID=44167939

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270661A EA201270661A1 (ru) 2009-12-18 2010-12-17 УСИЛИВАЮЩИЕ РАЗМНОЖЕНИЕ β-КЛЕТОК СОЕДИНЕНИЯ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Country Status (14)

Country Link
US (1) US20130023491A1 (ru)
EP (1) EP2513298A4 (ru)
JP (1) JP2013514781A (ru)
KR (1) KR20120113228A (ru)
CN (1) CN102803474A (ru)
AU (1) AU2010330823A1 (ru)
BR (1) BR112012014925A2 (ru)
CA (1) CA2784596A1 (ru)
EA (1) EA201270661A1 (ru)
IL (1) IL220401A0 (ru)
MX (1) MX2012007026A (ru)
SG (1) SG181703A1 (ru)
WO (1) WO2011075665A2 (ru)
ZA (1) ZA201204521B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103193781B (zh) * 2013-04-01 2015-12-23 济南大学 一种sahn酶蛋白的特异性抑制化合物及其合成方法
JP2016057488A (ja) * 2014-09-10 2016-04-21 株式会社ジャパンディスプレイ 自発光型表示装置
US11278616B2 (en) 2015-08-06 2022-03-22 Nitto Denko Corporation Immunity induction promoting composition, and vaccine pharmaceutical composition
TWI730980B (zh) 2015-08-26 2021-06-21 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
UA123637C2 (uk) 2016-03-10 2021-05-05 Янссен Фармацевтика Нв Заміщені аналоги нуклеозидів для застосування як інгібіторів prmt5
CN115626935A (zh) 2016-10-03 2023-01-20 詹森药业有限公司 用作prmt5抑制剂的单环和双环系统取代的卡巴核苷类似物
JP7225106B2 (ja) 2017-02-27 2023-02-20 ヤンセン ファーマシューティカ エヌ．ベー． Ｐｒｍｔ５阻害剤による治療に応答する癌患者の同定におけるバイオマーカーの使用
WO2018160534A1 (en) * 2017-02-28 2018-09-07 Joslin Diabetes Center Protection of beta cells from immune attack
WO2019100062A1 (en) 2017-11-20 2019-05-23 Ichan School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
WO2019110734A1 (en) 2017-12-08 2019-06-13 Janssen Pharmaceutica Nv Novel spirobicyclic analogues
WO2019136320A1 (en) * 2018-01-05 2019-07-11 Icahn School Of Medicine At Mount Sinai Method of increasing proliferation of pancreatic beta cells, treatment method, and composition
EP3768267A4 (en) 2018-03-20 2022-04-20 Icahn School of Medicine at Mount Sinai KINA INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US20220152072A1 (en) * 2019-04-05 2022-05-19 Prelude Therapeutics, Incorporated Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用ｐｒｍｔ５抑制劑治療癌症之方法
LV15670B (lv) * 2021-03-10 2023-11-20 Latvijas Organiskās Sintēzes Institūts Jauni adenozilmerkaptāna atvasinājumi kā vīrusu m-RNS kapinga metiltransferāžu inhibitori
WO2024118503A1 (en) 2022-11-28 2024-06-06 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547942A (en) * 1994-01-04 1996-08-20 Rapaport; Eliezer Method of treatment of diabetes mellitus by administration of adenosine 5'-t
WO2000047721A2 (en) * 1999-02-10 2000-08-17 Ontogeny, Inc. Methods of inducing insulin positive progenitor cells
EP1194168B1 (en) * 1999-06-23 2010-03-31 University Of Vermont And State Agricultural College Methods and products for manipulating uncoupling protein expression
US20040170705A1 (en) * 2001-03-08 2004-09-02 Dusan Miljkovic Compositions and methods for non-insulin glucose uptake
EP1511757B1 (en) * 2002-06-07 2015-11-04 Universitair Medisch Centrum Utrecht New compounds for modulating the activity of exchange proteins directly activated by camp (epacs)
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
WO2007075956A2 (en) * 2005-12-21 2007-07-05 The Govt. Of The Usa As Represented By The Secretary Of The Department Of Health & Human Services Methods for producing and using pancreatic endocrine cells
SI2421879T1 (sl) * 2009-04-22 2014-01-31 Institute Of Organic Chemistry And Biochemistry As Cr Novi 7-deazapurinski nukleozidi za terapevtske uporabe

Also Published As

Publication number Publication date
MX2012007026A (es) 2013-03-18
ZA201204521B (en) 2013-09-25
WO2011075665A2 (en) 2011-06-23
SG181703A1 (en) 2012-07-30
CN102803474A (zh) 2012-11-28
CA2784596A1 (en) 2011-06-23
JP2013514781A (ja) 2013-05-02
US20130023491A1 (en) 2013-01-24
AU2010330823A1 (en) 2012-07-05
IL220401A0 (en) 2012-08-30
KR20120113228A (ko) 2012-10-12
WO2011075665A3 (en) 2011-11-17
EP2513298A4 (en) 2013-03-27
EP2513298A2 (en) 2012-10-24
BR112012014925A2 (pt) 2017-03-01

Similar Documents

Publication Publication Date Title
EA201270661A1 (ru) УСИЛИВАЮЩИЕ РАЗМНОЖЕНИЕ β-КЛЕТОК СОЕДИНЕНИЯ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
ES2401192T8 (es) Deazapurinas útiles como inhibidores de janus cinasas
HN2009001165A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
BR112014003693A2 (pt) amino quinazolinas como inibidores de quinase
BR112013010484A2 (pt) derivados de coelenterazina e métodos de utilizar os mesmos
ECSP13012394A (es) Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
DK2089361T5 (da) Inhibitorer af natriumglucose-cotransportør 2 og fremgangsmåder til deres anvendelse
CY1116377T1 (el) Αναστολεις της ανθρωπινης πρωτεϊνικης φωσφατασης της τυροσινης και μεθοδοι χρησης
EA201270553A1 (ru) Ингибиторы тирозинкиназы брутона
PH12014501122A1 (en) Methods of treatment using an antibody against interferon gamma
ZA200808536B (en) Deazapurines useful as inhibitors of janus kinases
EA201201143A1 (ru) Производные пиразола в качестве ингибиторов jak
GT201200132A (es) Antagonistas il-17a
EA200901313A1 (ru) Ингибиторы тирозинкиназы брутона
NO20091423L (no) Pyrimidinderivater og deres anvendelse som kinaseinhibitorer
BRPI0900060A2 (pt) método e sistema para fabricar um artigo
EA201070473A1 (ru) Способ увеличения адсорбции ингибитора в области ствола скважины
SMT201400114B (it) Derivati di 2-arilimidazolo come inibitori dell'enzima pde10a
EA201270325A1 (ru) Способы лечения саркомы с использованием эпиметаболической сдвигающей добавки (кофермента q10)
EA201300867A1 (ru) ИНГИБИТОРЫ КИНАЗЫ mTOR В КАЧЕСТВЕ АНТИВИРУСНЫХ АГЕНТОВ
DE602007004333D1 (de) Inhibitoren von akt (proteinkinase b)
WO2012006243A3 (en) Methods and compositions for the specific inhibition of beta-catenin by double-stranded rna
WO2012174537A3 (en) Small molecule screening for mouse satellite cell proliferation
EA201200891A1 (ru) Производные 3,4,4a,10d-тетрагидро-1h-тиопирано[4,3-c]изохинолина